Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.86 million
Profitability
Miscellaneous
Employees189
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The company earned $18.34 million during the quarter, compared to the consensus estimate of $17.58 million. Teligent had a negative net margin of 46.67% and a negative return on equity of 102.17%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What price target have analysts set for TLGT?
2 equities research analysts have issued 1-year price objectives for Teligent's shares. Their predictions range from $3.00 to $3.00. On average, they expect Teligent's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 334.8% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
Media stories about TLGT stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teligent earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Teligent.
Are investors shorting Teligent?
Teligent saw a decline in short interest during the month of July. As of July 15th, there was short interest totalling 9,393,300 shares, a decline of 18.3% from the June 15th total of 11,492,600 shares. Based on an average trading volume of 411,400 shares, the days-to-cover ratio is currently 22.8 days. Currently, 21.6% of the company's stock are sold short. View Teligent's Current Options Chain.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include XOMA (XOMA), Axovant Sciences (AXON), GlycoMimetics (GLYC), Synlogic (SYBX), Lexicon Pharmaceuticals (LXRX), BioXcel Therapeutics (BTAI), Paratek Pharmaceuticals (PRTK), Strongbridge Biopharma (SBBP), Kala Pharmaceuticals (KALA), Bicycle Therapeutics (BCYC), Aldeyra Therapeutics (ALDX), Harrow Health (HROW), IDEAYA Biosciences (IDYA), Mersana Therapeutics (MRSN) and Generex Biotechnology (GNBT).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
Who are Teligent's major shareholders?
Teligent's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (7.08%), First Light Asset Management LLC (5.99%), Vanguard Group Inc. (4.66%), BlackRock Inc. (1.53%), Northern Trust Corp (0.90%) and NJ State Employees Deferred Compensation Plan (0.45%). Company insiders that own Teligent stock include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which major investors are selling Teligent stock?
Which major investors are buying Teligent stock?
TLGT stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, First Light Asset Management LLC, Paloma Partners Management Co, State of New Jersey Common Pension Fund D, SG Americas Securities LLC, Jane Street Group LLC, TENOR CAPITAL MANAGEMENT Co. L.P. and Morgan Stanley. Company insiders that have bought Teligent stock in the last two years include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $0.69.
How big of a company is Teligent?
Teligent has a market capitalization of $37.16 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Teligent employs 189 workers across the globe.View Additional Information About Teligent.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
